PHASE 1 READINESS
Right-sizing cGMP for first-in-human batches
What phase-appropriate quality really means in practice.
Bench To Batch / IRSG · Educational editorial draft · 6 min read
Phase-appropriate does not mean less accountable
Phase 1 material requires suitable manufacturing controls to protect subjects and ensure reliable product quality. The specific approach depends on modality, jurisdiction and risk.
Use a documented, risk-based approach
Evaluate equipment qualification, analytical suitability, contamination controls, materials management and release criteria with qualified quality and regulatory experts.
Build evidence as the program progresses
Process knowledge, stability data and method maturity should evolve with clinical development. Commercial validation expectations must not be indiscriminately applied or indiscriminately dismissed during early planning.
Educational planning content, not regulatory advice. Program-specific decisions require qualified quality, manufacturing and regulatory review. Editorial content should be reviewed by your IRSG team before publication.